COMPANY

Seed Therapeutics

Keywords: oncology Ewing sarcoma hepatocellular carcinoma tumors neurology Biliary Tract Cancer ST-01156

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · $30M · announced Sep 23, 2025 Company release ↗
Source quote
- Sep 23, 2025 · Company release ↗
  “SEED Therapeutics Completes $30 Million Series A-3 Financing King of Prussia, PA – September 23, 2025 – SEED Therapeutics, Inc.”
Raise Series A · $24M · announced Aug 6, 2024 Company release ↗
Source quote
- Aug 6, 2024 · Company release ↗
  “Concurrently, SEED has launched Series A-3 financing with a first close of $24 million from investors”

Raises announced in these releases: $54M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Dec 1, 2025 Trial start 1: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies source ↗
Sep 23, 2025 Raise Private equity round — Series A-3: $30M (total, as published), announced Sep 23, 2025. Source: company release on GlobeNewswire. source ↗
Sep 23, 2025 Raise Series A · $30M source ↗
Aug 6, 2024 Raise Series A · $24M source ↗

Dec 31, 2029 (ESTIMATED) · 1 · A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies · NCT07197554

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $30.0M. Last 2 years.

Sep 23, 2025 Private equity round — Series A-3: $30M (total, as published), announced Sep 23, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07197554	A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies	1	Recruiting	Dec 1, 2025	Dec 31, 2029 (estimated)